Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $690,952.50 in Stock

Key Points

• Endurance (Cayman) Ltd Svf, a major shareholder of Vir Biotechnology, sold 109,675 shares for a total of $690,952.50 on October 21st, reducing their ownership by 0.73%.
• Vir Biotechnology's stock is currently trading at $6.12, reflecting a 2.4% decline from the previous day.
• In recent quarterly earnings, Vir Biotechnology reported an EPS of ($0.80), missing estimates, with revenue down 60.5% year-over-year.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 109,675 shares of the stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $6.30, for a total transaction of $690,952.50. Following the transaction, the insider directly owned 15,010,284 shares of the company's stock, valued at $94,564,789.20. This represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own at least 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Monday, October 20th, Endurance (Cayman) Ltd Svf sold 220,535 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.20, for a total transaction of $1,367,317.00.
• On Thursday, October 16th, Endurance (Cayman) Ltd Svf sold 12,844 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.10, for a total transaction of $78,348.40.
• On Wednesday, October 15th, Endurance (Cayman) Ltd Svf sold 16,671 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.07, for a total transaction of $101,192.97.
• On Friday, October 10th, Endurance (Cayman) Ltd Svf sold 2,300 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.08, for a total transaction of $13,984.00.
• On Thursday, October 9th, Endurance (Cayman) Ltd Svf sold 249,060 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.14, for a total transaction of $1,529,228.40.
• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The stock was sold at an average price of $6.05, for a total transaction of $2,820,764.10.
• On Tuesday, October 7th, Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.60, for a total transaction of $403,944.80.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.69, for a total transaction of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The stock was sold at an average price of $5.56, for a total transaction of $2,503,901.52.

Vir Biotechnology Stock Down 2.4%

VIR traded down $0.15 on Wednesday, hitting $6.12. The company's stock had a trading volume of 1,292,552 shares, compared to its average volume of 1,534,586. The company's 50 day simple moving average is $5.24 and its 200-day simple moving average is $5.28. The firm has a market cap of $850.19 million, a P/E ratio of -1.53 and a beta of 1.27. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $14.45.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The business had revenue of $1.21 million during the quarter, compared to the consensus estimate of $2.38 million. Vir Biotechnology had a negative return on equity of 50.22% and a negative net margin of 2,895.94%.The firm's quarterly revenue was down 60.5% on a year-over-year basis. During the same period last year, the business posted ($1.02) earnings per share. Equities analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vir Biotechnology

Large investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in Vir Biotechnology in the 2nd quarter worth $35,000. GAMMA Investing LLC raised its position in Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company's stock worth $46,000 after purchasing an additional 5,972 shares during the period. Apollon Wealth Management LLC purchased a new position in Vir Biotechnology in the 2nd quarter worth $50,000. PNC Financial Services Group Inc. raised its position in Vir Biotechnology by 26.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,459 shares of the company's stock worth $68,000 after purchasing an additional 2,171 shares during the period. Finally, FORA Capital LLC purchased a new position in shares of Vir Biotechnology in the first quarter valued at about $70,000. Hedge funds and other institutional investors own 65.32% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on VIR. Bank of America raised Vir Biotechnology from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $12.00 to $14.00 in a research note on Wednesday, August 27th. HC Wainwright reissued a "buy" rating and set a $15.00 price objective on shares of Vir Biotechnology in a research note on Monday, September 15th. Evercore ISI began coverage on shares of Vir Biotechnology in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $12.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Vir Biotechnology in a research report on Tuesday, October 14th. Finally, Raymond James Financial began coverage on shares of Vir Biotechnology in a research report on Friday, July 11th. They set an "outperform" rating on the stock. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $17.30.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.